


## pBI-G Tet Vector Information

GenBank Accession No.: U89933

PT3068-5

Cat. No. 631004



**Restriction Map and Multiple Cloning Site (MCS) of pBI-G Tet Vector.** Unique restriction sites are shown in bold.

### Description

The pBI-G Tet Vector is a response plasmid that can be used to express a gene of interest and  $\beta$ -galactosidase from a bidirectional tet-responsive promoter ( $P_{bi-1}$ ; 1) in Clontech's Tet-On<sup>®</sup> and Tet-Off<sup>®</sup> Gene Expression Systems and Cell Lines (2). The Tet Expression Systems and Cell Lines give researchers ready access to the tetracycline-regulated expression systems described by Gossen & Bujard (3; Tet-Off) and Gossen *et al.* (4; Tet-On). The pBI-G Tet Vector contains the bidirectional promoter  $P_{bi-1}$ , which is responsive to the tTA and rtTA regulatory proteins in the Tet-Off and Tet-On systems, respectively.  $P_{bi-1}$  contains the Tet-responsive element (TRE), which consists of seven copies of the 42-bp tet operator sequence (*tetO*). The TRE element is between two minimal CMV promoters ( $P_{minCMV}$ ), which lack the enhancer that is part of the complete CMV promoter. Consequently,  $P_{bi-1}$  is silent in the absence of binding of TetR or rTetR to the *tetO* sequences.  $P_{minCMV-1}$  controls the expression of  $\beta$ -galactosidase; and  $P_{minCMV-2}$  controls the expression of the gene of interest. Therefore, the expression of a gene of interest for which there is no convenient assay may be monitored indirectly via the  $\beta$ -galactosidase reporter function. Note that the cloned insert must have an initiation codon. In some cases, addition of a Kozak consensus ribosome binding site (5) may improve expression levels; however, many cDNAs have been efficiently expressed in Tet systems without the addition of a Kozak sequence.

### Use

pBI-G allows the simultaneous regulation of both a gene of interest and  $\beta$ -galactosidase by one central TRE. After a stable Tet-Off or Tet-On cell line has been established by transfecting with a tTA or rtTA regulator plasmid, pBI-G is cotransfected with pTK-Hyg (Cat No. 631750) to permit selection of a double-stable cell line which expresses both the gene of interest and the  $\beta$ -galactosidase reporter gene. Alternatively, pPUR (Cat No. 631601) or another selection plasmid can be used. If this plasmid



United States/Canada  
800.662.2566

Asia Pacific  
+1.650.919.7300

Europe  
+33.(0)1.3904.6880

Japan  
+81.(0)77.543.6116

Clontech Laboratories, Inc.  
A Takara Bio Company  
1290 Terra Bella Ave.  
Mountain View, CA 94043  
Technical Support (US)  
E-mail: tech@clontech.com  
www.clontech.com

(PR05619; published 10 May 2000)

contains an enhancer element, as does pPUR, cointegration of pBI-G and the selection plasmid may lead to higher background expression. Double-stable, tet-responsive cell lines with pBI-G response constructs can be developed using the protocols described for pTRE response plasmids in the Tet Systems User Manual (PT3001-1). After the double-stable cell line is established, expression of  $\beta$ -galactosidase can be monitored using any standard assay.

### Location of Features

- Multiple cloning site (MCS): 7715–7
- $P_{bi-1}$  Bidirectional Tet-responsive promoter: 12–568
  - $P_{minCMV-2}$ : 122–12
  - Tet-responsive element (TRE): 128–439
  - $P_{minCMV-1}$ : 440–568
- *LacZ* gene
  - $\beta$ -galactosidase coding sequence: 647–3749
- Fragment containing the  $\beta$ -Globin poly A signal: 4013–5180
- Col E1 origin of replication: 5381–6024
- Ampicillin resistance gene
  - $\beta$ -lactamase coding sequences: 7032–6172
- Fragment containing the SV40 poly A signal: 7697–7246

### Propagation in *E. coli*

- Suitable host strains: DH5 $\alpha$  and other general purpose strains.
- Selectable marker: plasmid confers resistance to ampicillin (50  $\mu$ g/ml) on *E. coli* hosts.
- *E. coli* replication origin: Col E1

### References

1. Baron, U., *et al.* (1995) *Nucleic Acids Res.* **17**:3605–3606.
2. Tet Expression Systems and Cell Lines (July 1996) *Clontechniques XI*(3):2–5.
3. Gossen, M. & Bujard, H. (1992) *Proc. Natl. Acad. Sci. USA* **89**:5547–5551.
4. Gossen, M., *et al.* (1995) *Science* **268**:1766–1769.
5. Kozak, M. (1987) *Nucleic Acids Res.* **15**:8125–8148.

**Note:** The attached sequence file has been compiled from information in the sequence databases, published literature, and other sources, together with partial sequences obtained by Clontech. This vector has not been completely sequenced.

### Notice to Purchaser

Clontech products are to be used for research purposes only. They may not be used for any other purpose, including, but not limited to, use in drugs, *in vitro* diagnostic purposes, therapeutics, or in humans. Clontech products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products or to provide a service to third parties without written approval of Clontech Laboratories, Inc.

Use of the Tetracycline controllable expression systems (the “Tet Technology”) is covered by a series of patents including U.S. Patent Nos. 5,464,758 and 5,814,618, which are proprietary to TET Systems Holding GmbH & Co. KG. Academic research institutions are granted an automatic license with the purchase of this product to use the Tet Technology only for internal, academic research purposes, which license specifically excludes the right to sell, or otherwise transfer, the Tet Technology or its component parts to third parties. Notwithstanding the above, academic and not-for profit research institutions whose research using the Tet Technology is sponsored by for profit organizations, which shall receive ownership to all data and results stemming from the sponsored research, shall need a commercial license agreement from IP Merchandisers in order to use the Tet Technology. In accepting this license, all users acknowledge that the Tet Technology is experimental in nature. TET Systems Holding GmbH & Co. KG makes no warranties, express or implied or of any kind, and hereby disclaims any warranties, representations, or guarantees of any kind as to the Tet Technology, patents, or products. All others are invited to request a license from TET Systems Holding GmbH & Co. KG prior to purchasing these reagents or using them for any purpose. Clontech is required by its licensing agreement to submit a report of all purchasers of the Tet-controllable expression system to IP Merchandisers, Inc. For license information, please contact:

Hans Peter Kneubuehl  
TET Systems Holding GmbH & Co. KG  
Im Neuenheimer Feld 582  
69120 Heidelberg  
Germany  
Tel +49 6221 588 04 00  
Fax +49 6221 588 04 04

eMail: [kneubuehl@tet-systems.de](mailto:kneubuehl@tet-systems.de)

or use our electronic licensing request form via [http://www.tetsystems.com/main\\_inquiry.htm](http://www.tetsystems.com/main_inquiry.htm)

Clontech, the Clontech logo and all other trademarks are the property of Clontech Laboratories, Inc.  
Clontech is a Takara Bio Company. ©2006